Phil Ferneau

Ovation is a leading provider of genomic data for the life sciences industry. We are dedicated to supporting the advancement of precision medicine and offer access to a wide range of high-quality, consented genomic data linked to diverse, longitudinal phenotypic data at scale. Our data allows researchers to identify and validate biomarkers, discover new targets and understand resistance mechanisms in various populations. Our cloud-based LIMS system allows clinical labs to easily adopt innovative molecular tests, while also transforming samples into valuable research-grade data across various disease areas. Learn more at www.ovation.io.

For all the marvels of modern medicine, clinical research has failed to keep pace with digital innovation. Still reliant on siloed, inefficient approaches, today’s clinical trial operations do not reflect our always-connected digital society. Teckro was founded on the conviction that there is a better way. With Teckro’s interconnected digital protocol, study sites harness multimedia study resources intuitively interwoven with purpose-built communication channels to make fast, informed decisions at the point of care. Data-driven site engagement oversight gives sponsors early visibility of potential risk indicators, facilitating timely, proactive measures. With simple, integrated tools to share and analyze site surveys, sponsors foster a meaningful feedback loop that allows sites to feel heard - while their frontline insights contribute to study improvements and research progress. Our digital, intuitive solution is used by seven of the 10 largest pharma companies and emerging biotechs alike to manage trials on six continents, supporting all therapeutic areas, all phases and any trial model. Our values inspire us to continue modernizing and simplifying clinical research, make a lasting impact for patients and ultimately make the world a better place. Headquartered in Limerick, Ireland, we have locations across Europe and the United States. More is possible, with Teckro. Digitally interconnected sponsors, sites and monitors. Timely guidance and immediate answers anytime, anywhere. Can your protocol do that?

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. Were committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

Ovation is a leading provider of genomic data for the life sciences industry. We are dedicated to supporting the advancement of precision medicine and offer access to a wide range of high-quality, consented genomic data linked to diverse, longitudinal phenotypic data at scale. Our data allows researchers to identify and validate biomarkers, discover new targets and understand resistance mechanisms in various populations. Our cloud-based LIMS system allows clinical labs to easily adopt innovative molecular tests, while also transforming samples into valuable research-grade data across various disease areas. Learn more at www.ovation.io.

For all the marvels of modern medicine, clinical research has failed to keep pace with digital innovation. Still reliant on siloed, inefficient approaches, today’s clinical trial operations do not reflect our always-connected digital society. Teckro was founded on the conviction that there is a better way. With Teckro’s interconnected digital protocol, study sites harness multimedia study resources intuitively interwoven with purpose-built communication channels to make fast, informed decisions at the point of care. Data-driven site engagement oversight gives sponsors early visibility of potential risk indicators, facilitating timely, proactive measures. With simple, integrated tools to share and analyze site surveys, sponsors foster a meaningful feedback loop that allows sites to feel heard - while their frontline insights contribute to study improvements and research progress. Our digital, intuitive solution is used by seven of the 10 largest pharma companies and emerging biotechs alike to manage trials on six continents, supporting all therapeutic areas, all phases and any trial model. Our values inspire us to continue modernizing and simplifying clinical research, make a lasting impact for patients and ultimately make the world a better place. Headquartered in Limerick, Ireland, we have locations across Europe and the United States. More is possible, with Teckro. Digitally interconnected sponsors, sites and monitors. Timely guidance and immediate answers anytime, anywhere. Can your protocol do that?

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. Were committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.